Alzheimer's Disease

The findings provide fresh insights into the potential health risks posed by environmental plastics

At the ADLM 2025, Roche highlights advances in diagnostics, including digital health solutions, mass spectrometry, and expanded access to testing across care settings

The new “iPSC Platform to Model Alzheimer’s disease Risk” (IPMAR) resource will be made available to researchers worldwide

First blood-based in vitro diagnostic test to receive FDA clearance to help identify patients with amyloid pathology associated with Alzheimer’s disease

New test provides less invasive option, reduces reliance on PET scans, and increases diagnosis accessibility

In a proof-of-concept study, the test detected five key biomarkers of Alzheimer’s disease—more than current commercially available blood tests can measure

VeraBIND™ Tau is a new noninvasive test that offers 96 percent sensitivity and 90 percent specificity, empowering earlier and more accessible Alzheimer's detection

Better diagnostics for neurodegenerative diseases can improve clinical trials to help move groundbreaking therapies to approval

Trailblazing labs are among the first to adopt new tests and treatments for longstanding challenges

Mount Sinai Health System among the first in the world to use blood tests as an early detection tool for Alzheimer’s disease and related dementias in patients